PhRMA Urges Antitrust Exemption For Bioterrorism Research
An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says
You may also be interested in...
Aventis-Pasteur would prefer a guaranteed manufacturing agreement rather than incremental payments for bioterrorism countermeasures developed under "Project BioShield.
Liability protections under "Project BioShield" should be extended to companies that make unapproved bioterrorism countermeasures available in an emergency situation, the Biotechnology Industry Organization said
A "Project BioShield" provision that would allow government funding only for bioterrorism countermeasures for which no commercial market exists is understood to be a concern among pharmaceutical and biotech companies